Sullivan Ryan T 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Nov 19, 2019
Insider Transaction Report
Form 4
Sullivan Ryan T
General Counsel
Transactions
- Exercise/Conversion
Option to Purchase Common Stock
2019-11-19−8,325→ 26,475 totalExercise: $53.41Exp: 2028-02-13→ Common Stock (8,325 underlying) - Exercise/Conversion
Common Stock
2019-11-19$53.41/sh+8,325$444,638→ 34,043 total - Sale
Common Stock
2019-11-19$85.00/sh−8,325$707,625→ 25,718 total - Sale
Common Stock
2019-11-19$85.00/sh−3,829$325,465→ 21,889 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 13, 2018.